Vivus ($VVUS) has never had a marketing partner for flailing obesity therapy Qsymia--and now, it's about to be one short for erectile dysfunction therapy Stendra, too. Last week, Endo's ($ENDP) Auxilium Pharmaceuticals announced in a regulatory filing that it would be terminating its licensing pact--covering the U.S. and Canada--with the California drugmaker, with an end date of June 30. Now, Vivus--in desperate need of revenue as it stares down debt and a potential tab for a pricey Qsymia CV trial--will weigh its options and make an announcement by the end of 2016's first quarter as to how the company plans to take the drug forward. More from FiercePharmaMarketing